Minerva Neurosciences (NERV) – Investment Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for Minerva Neurosciences (NASDAQ: NERV):

• 12/8/2025 – Minerva Neurosciences had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/6/2025 – Minerva Neurosciences was upgraded by analysts at Wall Street Zen to a “sell” rating.
• 12/1/2025 – Minerva Neurosciences had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/24/2025 – Minerva Neurosciences had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/17/2025 – Minerva Neurosciences had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/6/2025 – Minerva Neurosciences had its price target lowered by analysts at HC Wainwright from $5.00 to $4.00. They now have a “neutral” rating on the stock.

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.